# Official Website: PhotoPharmics

**Type:** source
**Status:** Useful
**Confidence:** Medium
**Source Type:** Official Website
**URL:** https://photopharmics.com
**Publisher:** PhotoPharmics, Inc.
**Accessed:** 2026-06-19
**Updated:** 2026-06-19

## Summary

PhotoPharmics' official website describes a clinical-stage medical device company advancing investigational photo-neuromodulation for Parkinson's disease through Celeste®, a home-based, non-invasive light device studied for its effects on retinal and circadian signaling pathways.

## Useful Claims

- The company positions Celeste® as an investigational photo-neuromodulation device being evaluated for Parkinson's disease.
- The site emphasizes science exploring how light-responsive retinal pathways communicate with broader neurological systems.
- Celeste® is described as non-invasive (light delivered through the eyes, no surgery or implanted hardware) and home-based.
- Parkinson's disease affects more than 11 million people worldwide according to the site's disease-context copy.
- The company states its initial clinical focus is Parkinson's disease, with additional neurodegenerative applications possible through future research.
- Recent site news highlights a Phase 3 "Light for PD" trial nearing completion, Phase 2 results published in *Neurotherapeutics*, and board expansion to support clinical execution and commercialization.
- The site offers patient information, investor inquiry paths, and email updates for followers of the scientific and regulatory journey.

## Reliability Notes

This is an official company source. It is useful for product positioning, mechanism framing, and trial-status announcements, but efficacy claims, enrollment counts, and regulatory timelines should be cross-checked with clinical trial registries, peer-reviewed publications, and independent reporting before being treated as high-confidence evidence.

## Related Pages

- [PhotoPharmics](photopharmics.md)

## See Also

- [Light for PD clinical trial (clinicaltrials.gov)](https://clinicaltrials.gov/study/NCT04570033) — independent registry record for the pivotal study cited in legacy research